Want to see AU:ADR full AI Analyst Report?
ADR Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.19
Previous CloseN/A
Volume40.01K
Average Volume (3M)30.87K
Market Cap
AU$3.68M
Enterprise ValueAU$8.11M
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$2.40M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding54,887,672
10 Day Avg. Volume60,567
30 Day Avg. Volume30,874
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)-731.83
Price to Sales (P/S)449.48
P/FCF Ratio-63.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.73
Revenue Forecast (FY)AU$9.01M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2026 revenue rebound indicates that Adherium’s connected respiratory-health offering can regain commercial traction after weaker periods. If maintained, stronger sales would expand the base over which fixed costs are absorbed and provide a foundation for improving operating performance.
Positive Gross MarginA sustained positive gross margin shows that the company’s products generate economic value above direct costs, unlike the negative margins reported in earlier periods. This provides a platform for eventual operating leverage if revenue growth continues and overhead is brought into line.
Focused Digital Health ModelAdherium addresses a persistent healthcare need by combining inhaler-use data with software for patients, clinicians, and healthcare programs. This focused model gives the company a clearly defined role in respiratory disease management and supports relevance beyond a single temporary product cycle.
Bears Say
Severe UnprofitabilityThe scale of operating and net losses relative to revenue indicates that the cost base is not yet scaling with commercial activity. Unless expense intensity improves materially, even a revenue rebound may not translate into sustainable earnings or reduce the company’s ongoing need for capital.
Persistent Cash BurnConsistently negative operating and free cash flow means the business is consuming cash rather than funding itself internally. The large 2026 outflow can constrain investment in growth, increase dependence on external financing, and leave less flexibility to withstand continued operating losses.
Negative Equity And Higher DebtNegative shareholder equity materially weakens financial flexibility and signals that cumulative losses have eroded the capital base. Higher debt alongside that deficit increases financing pressure and makes it harder for the company to fund operations or absorb further losses without additional capital.
Adherium Ltd. News
ADR FAQ
What was Adherium Ltd.’s price range in the past 12 months?
Adherium Ltd. lowest share price was AU$0.06 and its highest was AU$0.19 in the past 12 months.
What is Adherium Ltd.’s market cap?
Adherium Ltd.’s market cap is AU$3.68M.
When is Adherium Ltd.’s upcoming earnings report date?
Adherium Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 122 days.
How were Adherium Ltd.’s earnings last quarter?
Adherium Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.151 earnings per share for the quarter.
Is Adherium Ltd. overvalued?
According to Wall Street analysts Adherium Ltd.’s price is currently Overvalued.
Does Adherium Ltd. pay dividends?
Adherium Ltd. does not currently pay dividends.
What is Adherium Ltd.’s EPS estimate?
Adherium Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adherium Ltd. have?
Adherium Ltd. has 54,887,672 shares outstanding.
What happened to Adherium Ltd.’s price movement after its last earnings report?
Adherium Ltd. reported an EPS of -AU$0.151 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Adherium Ltd.?
Currently, no hedge funds are holding shares in AU:ADR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adherium Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
1363.47%
Trailing 12-Months
Asset Growth
29.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adherium Ltd.
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
Technical Analysis
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―